The Curative Effect And Adverse Reactions Of The First-line Treatment Of CML-CP Were Observed In Nilotinib And Imatinib

Objective:To compare the efficacy and adverse reactions of patients with chronic myeloid leukemia chronic myeloid leukemia（CML-CP）in the first line of treatment with nilotinib and imatinib.Method:Choose 1¹2 months in a hospital in anhui province in 2017 was onset outpatient follow-up for chronic myeloid leukemia cells（CML-CP）and shall be to begin with,for taking nilotinib,and patients taking longer than 12 months,a total of 28cases of nilotinib for group,was collected at the same time for CML-CP and shall be taken to begin with imatinib,and duration of more than 12 months in patients with a total of 33 cases of imatinib group.The nilotinib group received 300 to 400mg of nilotinib and was treated with oral administration twice a day for 12 hours each time.The imatinib group was given to imatinib 400mg and was treated with oral treatment 1times a day.Medication after every 3 months,6 months,12 months of bone marrow biopsy examination,improve cytology and pathology,BCR-ABL^ISS transcription,chromosome karyotype detection,since drugs at the same time,regular monitoring of drug adverse reaction in the two groups.Compare two groups of patients after taking the target molecular biology reaction to obtain rate(3months BCR-ABL^IS≤10%,6months BCR-ABL^IS<1%,12 months BCR-ABL^IS≤0.1%),.3,6,12 months the main molecular biology reaction(MMR,BCR-ABL^IS≤0.1%)gain rate,3,6,12 months complete cytogenetic response（CCyR,Ph⁺=0）get rate and since drug adverse reaction occurred in the after.Results:The nilotinib group was superior to the imatinib group at the target molecular biological response rate.（78.6%vs 51.5%,85.7%vs 78.6%,51.5%vs24.2%,P<0.05）.in the early molecular(3months BCR-ABL^IS≤10%)),nilotinib for group,higher than imatinib group rate（78.6%vs 51.5%,P<0.05）;In the main reaction of molecular biology,two groups of 3,6,12 months of the main molecular biology reaction to obtain rate were 17.9%vs 9.1%,46.4%vs 21.2%,60.7%vs 24.2%,Nero was higher than imatinib group for 6,12 months when the difference was statistically significant（P<0.05）.In total cytogenetic responses,the CCyR rates of 3,6 and 12months in the two groups were 75.0%vs 69.7%,85.7%vs 75.8%,89.3%vs 78.8%,and the differences were not statistically significant（P>0.05）.In terms of adverse drug reactions,two groups of patients with hematology aspect adverse reactions characterized byⅠ^Ⅱlevel,moreⅢ^Ⅳrare adverse reactions,mostly self-limiting.Non hematologic adverse reactions of Nero for group,main show is bilirubin abnormalities,imatinib group is mainly characterized by edema,the majority of adverse reaction is lighter,Ⅲ^Ⅳrare adverse reactions,most patients can recover by themselves.Conclusion:The treatment of CML-CP patients treated with nilotinib was better,can make more patients get the target molecular biology reaction,and make more patients in the early molecular biology,and adverse drug reaction is lighter,high security,may become a first-line therapy for chronic myeloid leukemia.